References
Home page
1. About us. Sun Pharma. Accessed July 28, 2026. https://sunpharma.com/about-us/.
2. Advancing innovation globally for better patient care. Sun Pharma. Accessed July 28, 2026. https://sunpharma.com/wp-content/uploads/2026/07/Sun-Pharma_AR-2025-26.pdf.
3. de Jager H, Suleman F. The impact of generics and generic reference pricing on candesartan and rosuvastatin utilisation, price and expenditure in South Africa. Int J Clin Pharm. 2019;41(1):81–87. doi:10.1007/s11096-018-0758-x.
4. Suleman MU, Mursaleen M, Khalil U. Generic drugs: balancing efficacy, safety, and accessibility. INNOVAPATH. 2025;5(1). doi:10.63501/ft43yy69.
5. Quality. Sun Pharma. Accessed July 28, 2026. https://sunpharma.com/quality/.
Living with type 2 diabetes
1. Type 2 diabetes. Cleveland Clinic. Accessed July 29, 2026. https://my.clevelandclinic.org/health/diseases/21501-type-2-diabetes.
2. Diabetes. WHO. Accessed July 29, 2026. https://www.who.int/europe/news-room/fact-sheets/item/diabetes.
3. Okonta HI, Ikombele JB, Ogunbanjo GA. Knowledge, attitude and practice regarding lifestyle modification in type 2 diabetic patients. Afr J Prim Health Care Fam Med. 2014;6(1):E1–E6. doi:10.4102/phcfm.v6i1.655.
4. Ardisson Korat AV, Willett WC, Hu FB. Diet, lifestyle, and genetic risk factors for type 2 diabetes: a review from the nurses’ health study, nurses’ health study 2, and health professionals’ follow-up study. Curr Nutr Rep. 2014;3(4):345–354. doi:10.1007/s13668-014-0103-5.
5. Mugharbel KM, Al-Mansouri MA. Prevalence of obesity among type 2 diabetic patients in Al-Khobar primary health care centers. J Family Community Med. 2003;10(2):49–53.
6. Nguyen NT, Nguyen XM, Lane J, et al. Relationship between obesity and diabetes in a US adult population: findings from the National Health and Nutrition Examination Survey, 1999–2006. Obes Surg. 2011;21(3):351–355. doi:10.1007/s11695-010-0335-4.
7. Diabetes and smoking. CDC. Accessed July 29, 2026. https://www.cdc.gov/diabetes/risk-factors/diabetes-and-smoking.html.
8. Baliunas DO, Taylor BJ, Irving H, et al. Alcohol as a risk factor for type 2 diabetes. Diabetes Care. 2009;32(11):2123–2132. doi:10.2337/dc09-0227.
9. Colberg SR, Sigal RJ, Yardley JE, et al. Physical activity/exercise and diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2016;39(11):2065–2079. doi:10.2337/dc16-1728.
10. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022: a consensus report by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2022;45(11):2753–2786.
11. Biguanides. Cleveland Clinic. Accessed July 29, 2026. https://my.clevelandclinic.org/health/treatments/25004-biguanides.
12. Sulfonylureas. Cleveland Clinic. Accessed July 29, 2026. https://my.clevelandclinic.org/health/treatments/sulfonylureas.
13. Thiazolidinediones. Cleveland Clinic. Accessed July 29, 2026. https://my.clevelandclinic.org/health/treatments/thiazolidinediones.
14. GLP-1 agonists. Cleveland Clinic. Accessed July 28, 2026. https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists.
15. SGLT2 inhibitors. Cleveland Clinic. Accessed July 28, 2026. https://my.clevelandclinic.org/health/treatments/sglt2-inhibitors.
16. Alpha-glucosidase inhibitors. Cleveland Clinic. Accessed July 28, 2026. https://my.clevelandclinic.org/health/treatments/alpha-glucosidase-inhibitors.
17. Oral diabetes medications. Cleveland Clinic. Accessed July 28, 2026. https://my.clevelandclinic.org/health/articles/12070-oral-diabetes-medications.
18. Injectable insulin medications. Cleveland Clinic. Accessed July 30, 2026. https://my.clevelandclinic.org/health/drugs/13902-injectable-insulin-medications.
19. Emerging therapies in the treatment of type 2 diabetes. Cleveland Clinic Pharmacotherapy Update. Accessed July 30, 2026. https://www.clevelandclinicmeded.com/medicalpubs/pharmacy/janfeb2005/type2.htm.
20. Dulaglutide injection. Cleveland Clinic. Accessed July 28, 2026. https://my.clevelandclinic.org/health/drugs/20265-dulaglutide-injection.
21. Exenatide solution for injection. Cleveland Clinic. Accessed July 28, 2026. https://my.clevelandclinic.org/health/drugs/20513-exenatide-solution-for-injection.
22. Exenatide extended-release suspension for injection. Cleveland Clinic. Accessed July 28, 2026. https://my.clevelandclinic.org/health/drugs/18447-exenatide-extended-release-suspension-for-injection.
23. Liraglutide injection (diabetes). Cleveland Clinic. Accessed July 28, 2026. https://my.clevelandclinic.org/health/drugs/20558-liraglutide-injection-diabetes.
24. Lixisenatide injection. Cleveland Clinic. Accessed July 28, 2026. https://my.clevelandclinic.org/health/drugs/19925-lixisenatide-injection.
25. Sun Pharmaceutical Industries Ltd. Data on file: Lixisenatide professional information. September 2024.
26. Rizvi AA, Rizzo M. The emerging role of dual GLP-1 and GIP receptor agonists in glycemic management and cardiovascular risk reduction. Diabetes Metab Syndr Obes. 2022;15:1023–1030. doi:10.2147/DMSO.S351982.
27. Seino Y, Fukushima M, Yabe D. GIP and GLP‐1, the two incretin hormones: similarities and differences. J Diabetes Investig. 2010;1(1–2):8–23. doi:10.1111/j.2040-1124.2010.00022.x.
28. Sorli C, Harashima S-I, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes: the SUSTAIN 1 randomized clinical trial. Lancet Diabetes Endocrinol. 2017;5(4):251–260.
29. What is the A1C test? American Diabetes Association. Accessed June 11, 2026. https://diabetes.org/about-diabetes/a1c.
What is a GLP-1?
1. Collins L, Costello RA. Glucagon-like peptide-1 receptor agonists. In: StatPearls. StatPearls Publishing; 2026. Accessed July 28, 2026. http://www.ncbi.nlm.nih.gov/books/NBK551568/.
2. GLP-1 agonists. Cleveland Clinic. Accessed July 28, 2026. https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists.
3. SEMAGARD Patient Information Leaflet, June 2026.
How to use a GLP-1
1. Collins L, Costello RA. Glucagon-like peptide-1 receptor agonists. In: StatPearls. StatPearls Publishing; 2026. Accessed July 28, 2026. http://www.ncbi.nlm.nih.gov/books/NBK551568/.
2. GLP-1 agonists. Cleveland Clinic. Accessed July 28, 2026. https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists.
3. Oral GLP-1 analogues (semaglutide). Gateshead Health. Accessed July 29, 2026. https://www.gatesheadhealth.nhs.uk/resources/oral-glp-1-analogues-semaglutide/.
4. Sun Pharmaceutical Industries Ltd. Data on file: Lixisenatide professional information. September 2024.
5. SEMAGARD Patient Information Leaflet, June 2026.
6. Hirsch LJ, Strauss KW. The injection technique factor: what you don’t know or teach can make a difference. Clin Diabetes. 2019;37(3):227–233. doi:10.2337/cd18-0076.
Get your GLP-1 from a trusted pharmacy
1. Thinking of using a compounding pharmacy? What you need to know. Harvard Health. Accessed July 29, 2026. https://www.health.harvard.edu/healthy-aging-and-longevity/thinking-of-using-a-compounding-pharmacy-what-you-need-to-know.
2. Collins L, Costello RA. Glucagon-like peptide-1 receptor agonists. In: StatPearls. StatPearls Publishing; 2026. Accessed July 28, 2026. http://www.ncbi.nlm.nih.gov/books/NBK551568/.
3. Gudeman J, Jozwiakowski M, Chollet J, et al. Potential risks of pharmacy compounding. Drugs in R&D. 2013;13(1):1–8. doi:10.1007/s40268-013-0005-9.
4. Court case looms as pharmacy challenges SAHPRA raid. JUTA Medical Brief. Accessed July 30, 2026. https://www.medicalbrief.co.za/court-challenge-looms-as-pharmacy-challenges-sahpra-raid/.
5. Who we are. South African Health Products Regulatory Authority. Accessed August 5, 2026. https://www.sahpra.org.za/who-we-are/.
FAQs
1. Collins L, Costello RA. Glucagon-like peptide-1 receptor agonists. In: StatPearls. StatPearls Publishing; 2026. Accessed July 28, 2026. http://www.ncbi.nlm.nih.gov/books/NBK551568/.
2. GLP-1 agonists. Cleveland Clinic. Accessed July 28, 2026. https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists.
3. Gonzalez-Rellan MJ, Drucker DJ. The expanding benefits of GLP-1 medicines. Cell Rep Med. 2025;6(7):102214. doi:10.1016/j.xcrm.2025.102214.
4. Oral GLP-1 analogues (semaglutide). Gateshead Health. Accessed July 29, 2026. https://www.gatesheadhealth.nhs.uk/resources/oral-glp-1-analogues-semaglutide/.
5. SEMAGARD Patient Information Leaflet, June 2026.
6. Hirsch LJ, Strauss KW. The injection technique factor: what you don’t know or teach can make a difference. Clin Diabetes. 2019;37(3):227–233. doi:10.2337/cd18-0076.
7. Type 2 diabetes. Cleveland Clinic. Accessed July 29, 2026. https://my.clevelandclinic.org/health/diseases/21501-type-2-diabetes.
8. Colberg SR, Sigal RJ, Yardley JE, et al. Physical activity/exercise and diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2016;39(11):2065–2079. doi:10.2337/dc16-1728.
9. Generic semaglutide: frequently asked questions. MedExpress Canada. Accessed July 31, 2026. https://medexpressca.zendesk.com/hc/en-gb/articles/36261135392541-Generic-Semaglutide-Frequently-Asked-Questions.
10. Suleman MU, Mursaleen M, Khalil U. Generic drugs: balancing efficacy, safety, and accessibility. INNOVAPATH. 2025;5(1). doi:10.63501/ft43yy69.
Resources
1. Saving lives through diabetes information, education and support. Diabetes South Africa. Accessed July 30, 2026. https://www.diabetessa.org.za/.
2. Life can be sweet, with diabetes. Sweet Life Diabetes Community. Accessed July 30, 2026. https://sweetlife.org.za/.
3. About us. Youth with Diabetes. Accessed July 30, 2026. https://www.youthwithdiabetes.com/.
4. SA Diabetes Advocacy is the united voice for people with diabetes. SA Diabetes Advocacy. Accessed July 20, 2026. https://www.diabetesadvocacy.org.za/.
5. Welcome to living GREAT with diabetes. Stellenbosch University. Accessed July 30, 2026. https://great.sun.ac.za/.
6. Your partner in diabetes. Centre for Diabetes and Endocrinology. Accessed July 30, 2026. https://cdediabetes.co.za/.
7. We’re celebrating 45 years of heart and brain health. The Heart and Stroke Foundation South Africa. Accessed July 30, 2026. https://www.heartfoundation.co.za/.